Adrenal Insufficiency Clinical Trial
Official title:
An Open Label, Partially Randomised, Single Dose, Crossover Study to Evaluate the PK, Oral Bioavailability and Relationship to Metabolic Parameters of Hydrocortisone and Infacort® in Healthy Adult Male Volunteers.
Verified date | April 2022 |
Source | Diurnal Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will investigate a new drug called Infacort®; a newly-developed immediate release formulation of a well-established drug called hydrocortisone. Hydrocortisone is used as a replacement treatment for people whose adrenal glands are not producing enough natural cortisol - a condition known as adrenal insufficiency. The study will assess how Infacort® acts once inside the body, by measuring cortisol and other hormone levels in the body, compared to already marketed hydrocortisone tablet and hydrocortisone intravenous (through the vein) injection. The population who are eligible to take part in the study are healthy male volunteers, aged between 18 and 60 years of age.
Status | Completed |
Enrollment | 14 |
Est. completion date | November 2014 |
Est. primary completion date | November 2014 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: - Healthy male volunteers between 18 and 60 years of age, inclusive (at screening). - Subjects with a Body Mass Index (BMI) of 21-28. Body Mass Index = Body weight (kg) / (Height (m))*2. - Subjects with no clinically significant abnormal serum biochemistry, haematology and urinalysis values within 14 days prior to Day 1 of Study Period 1. - Subjects with a negative urinary drugs of abuse screen, determined within 14 days prior to Day 1 of Study Period 1. A positive alcohol test may be repeated at the discretion of the Investigator. - Subjects with negative HIV and Hepatitis B and C results. - Subjects with no clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 14 days prior to Day 1 of Study Period 1. - Subjects with no clinically-significant deviation outside the normal ranges for blood pressure and pulse measurements. - Subjects (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) and sexual partners must use effective contraception methods during the trial and for 3 months after the last dose, for example: - Oral contraceptive + condom - Intra-uterine device (IUD) + condom - Diaphragm with spermicide + condom - Subjects must be available to complete the study. - Subjects must satisfy a medical examiner about their fitness to participate in the study. - Subjects must provide written informed consent to participate in the study. Exclusion Criteria: - A clinically significant history of gastrointestinal disorder likely to influence drug absorption. - Receipt of regular medication within 14 days prior to Day 1 of Study Period 1 (including high dose vitamins, dietary supplements or herbal remedies). - Receipt of any vaccination within 14 days prior to Day 1 of Study Period 1. - Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction. - Presence of clinically significant infections (systemic fungal and viral infections, acute bacterial infections). - Current or previous history of tuberculosis. - A clinically significant history of previous allergy / sensitivity to Hydrocortisone and/or Dexamethasone. - A clinically significant history or family history of psychiatric disorders/illnesses. - A clinically significant history of drug or alcohol abuse. - Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function). - Participation in a New Chemical Entity clinical study within the previous 4 months or a marketed drug clinical study within the previous 3 months. (N.B. The washout period between trials is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study) - Subjects who have consumed more than 2 units of alcohol per day within seven (7) days prior to Day 1 of Study Period 1or have consumed any alcohol within the 48 hour period prior to Day 1 of Study Period 1. - Donation of 450ml or more of blood within the previous 3 months. - Subjects who smoke (or ex-smokers who have smoked within 6 months prior to Day 1 of Study Period 1). - Subjects who work shifts (i.e. regularly alternate between days, afternoons and nights). |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Simbec Research Limited | Merthyr Tydfil |
Lead Sponsor | Collaborator |
---|---|
Diurnal Limited | Simbec Research |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum Serum Concentration (Cmax) | Derived PK for Serum Cortisol: Maximum serum concentration (Cmax) | Hourly from 0 to 24 hours | |
Primary | AUC0-t | Derived PK for Serum Cortisol: Area under the curve from 0-24 hours | Hourly from 0 to 24 hours | |
Secondary | Adverse Events (AEs) | Number of subjects with adverse events throughout the study. | Days 1-2 during each Study Period | |
Secondary | Concentrations of Cortisol Binding Protein | Cortisol protein binding under physiological conditions and after the administration of dexamethasone and hydrocortisone. | Blood samples on Day 1 and/or Day 2 of each Study Period | |
Secondary | Insulin Sensitivity Under Physiological Conditions and After Administration of Dexamethasone and Infacort®, Hydrocortisone Tablets and i.v Hydrocortisone. | A standardised mixed meal elevates blood glucose and provides a reproducible stimulation of insulin release. Lower levels of insulin secretion, whilst maintaining normoglycaemia would indicate enhanced insulin sensitivity and glucose disposal; higher insulin levels will reflect insulin resistance. | Blood samples on Day 1 and/or Day 2 of each Study Period | |
Secondary | PK and Metabolism of Cortisol | Blood: Serum cortisol under physiological conditions and after administration of dexamethasone and InfacortĀ® Granules, Hydrocortisone Tablets and i.v Hydrocortisone Injection. | Blood, urine & saliva samples on Day 1 and/or Day 2 of each Study Period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT03282487 -
Optimising Steroid Replacement in Patients With Adrenal Insufficiency
|
Phase 4 | |
Not yet recruiting |
NCT05716607 -
Treatment Study in Patients Treated With Both Insulin & Hydrocortisone
|
N/A | |
Not yet recruiting |
NCT06435481 -
Tolerability and Acceptance of Two Oral Hydrocortisone Compounding Formulation for Pediatrics
|
Phase 4 | |
Recruiting |
NCT03399383 -
Adherence in Chronic Adrenal Insufficiency
|
N/A | |
Completed |
NCT01428336 -
Value of 25 mcg Cortrosyn Stimulation Test
|
N/A | |
Completed |
NCT00851942 -
Determination of Method-specific Normal Cortisol and Adrenal Hormone Responses to the Short Synacthen Test
|
Phase 4 | |
Withdrawn |
NCT00368381 -
Hydrocortisone Versus Hydrocortisone Plus Fludrocortisone for the Treatment of Adrenal Insufficiency in Severe Sepsis
|
Phase 4 | |
Active, not recruiting |
NCT04519580 -
Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
|
||
Recruiting |
NCT06008184 -
Real-time Monitoring of Cortisol - Comparison of Cortisol Levels in Four Biological Fluids
|
||
Completed |
NCT03013166 -
THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insufficiency Prescribed Hydrocortisone: Immediate, or Modified Release, or Prednisolone
|
||
Enrolling by invitation |
NCT02282150 -
Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism
|
Phase 4 | |
Completed |
NCT02934399 -
Dynamic Hormone Diagnostics in Endocrine Disease
|
||
Completed |
NCT03000231 -
Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency
|
||
Completed |
NCT00552487 -
Isolated ACTH Deficiency in Patients With Hashimoto Thyroiditis
|
N/A | |
Completed |
NCT00575341 -
Dehydroepiandrosterone Substitution in Adolescent and Young Women With Central Adrenal Insufficiency
|
Phase 3 | |
Completed |
NCT00471900 -
Six Months DHEA Treatment in Female Adrenal Failure
|
N/A | |
Completed |
NCT03294876 -
Rheumatoid Arthritis Adrenal Recovery Study
|
||
Completed |
NCT03709381 -
Effect of Adrenocorticotropic Hormone on Vascular Endothelial Growth Factor Release in Children Study
|
Early Phase 1 | |
Recruiting |
NCT05639127 -
The Treatment of Adrenal Crisis With Inhaled Prednisolone
|
Early Phase 1 | |
Completed |
NCT04488432 -
Endocrine, Bone And Metabolic Disorders In Adults After Allogeneic Stem-cell Transplant
|